Abstract
Doxorubicin (DOX) treatment (12 μg/g body weight, once a week for 2 weeks) resulted in a significant decrease in the heart rate along with an increase in QRS, ST, and QT intervals. Histopathological studies showed cardiomyocyte degeneration, cytoplasmic vacuolation and macrophage infiltration in cardiac tissue. A marked increase in the rate of apoptosis was also observed. An increased oxidative stress was evidenced by significantly higher levels of lipid peroxidation (LPO) and depletion of reduced glutathione. A decrease in the activity of cellular antioxidant defence enzymes was also observed. The decrease in the heart rate and ECG alterations were prevented significantly by AAILE (100 μg/g body weight, po) co-treatment, started two weeks prior to DOX treatment and continued till the termination of the experiment. The cardioprotection was also evident from histopathology and decrease in the rate of apoptosis in cardiomyocytes. AAILE co-treatment also prevented DOX-induced increase in LPO and decrease in antioxidant defence enzymes. The results suggest that AAILE administration prevents DOX-induced cardiotoxicity.
| Original language | English |
|---|---|
| Pages (from-to) | 323-331 |
| Number of pages | 9 |
| Journal | Indian Journal of Experimental Biology |
| Volume | 52 |
| Issue number | 4 |
| Publication status | Published - 01-01-2014 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Biotechnology
- Cell Biology
- Molecular Biology
Cite this
}
Protective effect of Azadirachta indica A. Juss against doxorubicin-induced cardiac toxicity in tumour bearing mice. / Koul, Ashwani; Goyal, Renu; Bharati, Sanjay.
In: Indian Journal of Experimental Biology, Vol. 52, No. 4, 01.01.2014, p. 323-331.Research output: Contribution to journal › Article
TY - JOUR
T1 - Protective effect of Azadirachta indica A. Juss against doxorubicin-induced cardiac toxicity in tumour bearing mice
AU - Koul, Ashwani
AU - Goyal, Renu
AU - Bharati, Sanjay
PY - 2014/1/1
Y1 - 2014/1/1
N2 - Doxorubicin (DOX) treatment (12 μg/g body weight, once a week for 2 weeks) resulted in a significant decrease in the heart rate along with an increase in QRS, ST, and QT intervals. Histopathological studies showed cardiomyocyte degeneration, cytoplasmic vacuolation and macrophage infiltration in cardiac tissue. A marked increase in the rate of apoptosis was also observed. An increased oxidative stress was evidenced by significantly higher levels of lipid peroxidation (LPO) and depletion of reduced glutathione. A decrease in the activity of cellular antioxidant defence enzymes was also observed. The decrease in the heart rate and ECG alterations were prevented significantly by AAILE (100 μg/g body weight, po) co-treatment, started two weeks prior to DOX treatment and continued till the termination of the experiment. The cardioprotection was also evident from histopathology and decrease in the rate of apoptosis in cardiomyocytes. AAILE co-treatment also prevented DOX-induced increase in LPO and decrease in antioxidant defence enzymes. The results suggest that AAILE administration prevents DOX-induced cardiotoxicity.
AB - Doxorubicin (DOX) treatment (12 μg/g body weight, once a week for 2 weeks) resulted in a significant decrease in the heart rate along with an increase in QRS, ST, and QT intervals. Histopathological studies showed cardiomyocyte degeneration, cytoplasmic vacuolation and macrophage infiltration in cardiac tissue. A marked increase in the rate of apoptosis was also observed. An increased oxidative stress was evidenced by significantly higher levels of lipid peroxidation (LPO) and depletion of reduced glutathione. A decrease in the activity of cellular antioxidant defence enzymes was also observed. The decrease in the heart rate and ECG alterations were prevented significantly by AAILE (100 μg/g body weight, po) co-treatment, started two weeks prior to DOX treatment and continued till the termination of the experiment. The cardioprotection was also evident from histopathology and decrease in the rate of apoptosis in cardiomyocytes. AAILE co-treatment also prevented DOX-induced increase in LPO and decrease in antioxidant defence enzymes. The results suggest that AAILE administration prevents DOX-induced cardiotoxicity.
UR - http://www.scopus.com/inward/record.url?scp=84898415956&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84898415956&partnerID=8YFLogxK
M3 - Article
C2 - 24772935
AN - SCOPUS:84898415956
VL - 52
SP - 323
EP - 331
JO - Journal of scientific & industrial research. C. Biological sciences
JF - Journal of scientific & industrial research. C. Biological sciences
SN - 0019-5189
IS - 4
ER -